University of Buffalo Prepares Melatonin Trial Targeting Mild to Moderate COVID-19

University of Buffalo Prepares Melatonin Trial Targeting Mild to Moderate COVID-19

Could the natural sleep aid melatonin serve as a treatment for patients with mild and moderate COVID-19? Apparently, researchers at the University at Buffalo seek to find out, and the university Institutional Review Board granted approval to proceed. The U.S. Food and Drug Administration (FDA) already granted approval of the Investigational New Drug (IND) Application.

Any Evidence?

That melatonin would be considered for a clinical trial caught TrialSite’s attention. Hence a brief literature review.  A recent study out of Iran summarized existing evidence on melatonin therapy for viral infections with focus on underlying mechanisms of melatonin actions. In another study, a group based out of China and UT San Antonio proposes that melatonin should be included in adjuvant treatment for COVID-19 as it has proven mechanisms to target inflammasomes that trigger cytokine storms and acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2. 

The Study

Led by Sanjay Sethi, MD, director of UB’s Clinical Research Office and Deputy Director of the university’s Clinical and Translational Institute, UB’s randomized, double-blind, placebo-controlled pilot clinical trial (NCT044...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee